A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Investigate the Effects of Ethanol and L-000830982 on Essential Tremor.

No registrations found.

Ethical review Positive opinion

Status Recruitment stopped

Health condition type -

Study type Interventional

Summary

ID

NL-OMON22574

Source

Nationaal Trial Register

Brief title

N/A

Health condition

Outpatient intervention study.

Sponsors and support

Primary sponsor: Centre for Human Drug Research

Intervention

Outcome measures

Primary outcome

The sensitivity and specificity of Actiwatch and DynaPort MiniMod in discriminating tremor movements from other movements holding the clinical accelerometry/myography-based tremography as the gold standard.

Secondary outcome

- 1. Tremor intensity, measured by average acceleration amplitude (iV);
- 2. Tremor duration measured by average duration of epochs classified as tremor (sec);
- 3. Tremor amount, measured by proportion of tremor movements per time unit (min/hr);
- 4. Tremor Clinical Rating Scale.

Study description

Background summary

In the current study, ambulatory methods for measuring tremor will be compared against a gold-standard laboratory tremography method to determine their utility for outpatient proof-of-concept studies. Additionally, the effects of L-000830982 and ethanol infusion on tremor will be determined and compared to placebo. This will be studied in a double-blind, double-dummy, randomized, placebo-controlled, 3-Period, crossover study.

Study objective

- 1. The effect of a single oral dose of L-000830982 versus oral placebo and an intravenous infusion of ethanol versus placebo on tremor over a 8-hour period in men and women with essential tremor will be estimated:
- 2. The sensitivity and specificity of laboratory tremography versus 2 ambulant tremography methods in classifying tremor movements versus other movements over a 8-hour period in men and women with essential tremor will be estimated.

Study design

N/A

Intervention

- 1. L-000830982 2.0 mg PO or placebo;
- 2. EtOH, infused at a rate to maintain a plasma concentration of ~0.6 g/L (4 hrs) or placebo
 - 2 A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 3-Period, Crossove ... 25-05-2025

Contacts

Public

Center for Human Drug Research (CHDR),

Zernikedreef 10

S.L. Haas, de

Zernikedreef 10

Leiden 2333 CL

The Netherlands

+31 (0)71 5246400

Scientific

Center for Human Drug Research (CHDR),

Zernikedreef 10

S.L. Haas, de

Zernikedreef 10

Leiden 2333 CL

The Netherlands

+31 (0)71 5246400

Eligibility criteria

Inclusion criteria

- 1. Men and women;
- 2. At least 18 years of age;
- 3. Essential Tremor diagnosed by a neurologist;
- 4. General good health;
- 5. Tremor symptoms present for > 6 months and relieved by ethanol.

Exclusion criteria

- 1. Medical condition interfering with clinical evaluations or conduct of the study;
- 2. Smoking > 5 cigarettes per day;
 - 3 A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 3-Period, Crossove ... 25-05-2025

- 3. Blood donation > 500 ml in previous 3 months;
- 4. Participation clinical trial within previous 3 months;
- 5. Medication use.

Study design

Design

Study type: Interventional

Intervention model: Crossover

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Placebo

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 06-07-2005

Enrollment: 9

Type: Actual

Ethics review

Positive opinion

Date: 15-09-2005

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

4 - A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 3-Period, Crossove ... 25-05-2025

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

RegisterIDNTR-newNL374NTR-oldNTR414Other: P05.058

ISRCTN ISRCTN71182680

Study results

Summary results

N/A